Sanford Health invests up to $20M in stem cell device company
One of the largest hospital networks in the U.S., Sanford Health, has committed up to $20 million to help progress InGeneron's adipose-derived stem cell program.
Regenerative medicine can rejuvenate healthcare
Self-regeneration designed to harness the body’s inherent power to heal itself is already improving lives and changing medical practices in many parts of the world.
presented by
The Top 5 Home Care Franchise Opportunities in the U.S.
The home care industry is booming. As Baby Boomers age and more families seek in-home solutions for loved ones, demand for home care services is at an all-time high.
Artificial pancreas-maker ViaCyte has new trials, funding, and Janssen partnership
San Diego’s ViaCyte is clearly up to plenty – the regenerative medicine company just announced it has teamed up with Janssen Research & Development, securing $20 million in financing in the process. As part of the deal, the pharma giant gains rights to evaluate clinical efficacy of ViaCyte’s Type 1 diabetes treatment – an artificial […]
EpiBone helps patients “grow their own bone”
New York regenerative medicine startup EpiBone‘s tagline is apt: “Grow your own bone.” It uses a patient’s own stem cells to create transplantable, highly personalized bone grafts, going after a 900,000-strong market of patients that need some variety of bone graft to treat, say, severe bone trauma, growth defects or genetic disorders. The company is showcased as one […]
First efficacy trial of Athersys stem cell therapy yields disappointing interim results. So what now?
Edited to include comments from CEO. Halfway through its first large-scale efficacy trial, Athersys’s experimental stem cell therapy did not provide significant benefit to patients with moderate-to-severe ulcerative colitis. But the company isn’t too worried about what that might mean just yet. Cleveland-based Athersys (NASDAQ: ATHX) released the interim results today for the Phase 2 […]
Stem cell company Athersys eyes potential new opportunities for its stroke therapy in Japan
Athersys (NYSE:ATHX) is looking to Japan for potential opportunities to bring its MultiStem therapies to market quicker. In its annual financial results call on Thursday, Athersys’ chief operating officer, BJ Lehmann, explained that legislation passed last fall in Japan could allow for conditional approval of new regenerative medicines that demonstrate strong safety profiles in clinical […]
What Are Healthcare Organizations Getting Wrong about Email Security?
A new report by Paubox calls for healthcare IT leaders to dispose of outdated assumptions about email security and address the challenges of evolving cybersecurity threats.
Neuro drug developer iPierian nets $30M, spins off new company for rare disease R&D program
Rather than leveraging stem cells for therapeutic use, iPierian Inc. has been using them to create disease models with which is can screen and develop new drugs. Now, with $30 million it’s just collected from investors, iPierian Inc. plans to split two distinct R&D programs that have emerged from those techniques into different companies. Some […]
5 more must-know emerging tech trends for healthcare innovators (readers’ version)
Once the healthcare innovator’s guide to must-know tech terms for the next decade of medicine hit on Monday, the feedback started coming in. It’s continued to trickle in via email, Twitter and LinkedIn all week. (Thank you!) MedCity News readers had some interesting ideas about technologies they think everyone in the healthcare space needs to […]
Cell therapy — the missing link for a true artificial pancreas for type 1 diabetes?
A closed-loop system of devices referred to as the artificial pancreas has been called the “holy grail” for Type 1 diabetes. Some scientists, though, think the future of diabetes treatment lies not in glucose meters and insulin pumps but in cell-based therapies with the potential to eliminate the need for daily insulin injections. Islet cell […]
Texas stem cell tech company raises $2.3 million, seeks $5.6 more
StemBioSys, a San Antonio company that manufactures and develops stem cell technologies in the regenerative medicine field, has landed $2,377,802. It still seeks $5,622,198, according to the regulatory filing. The company is in a quiet period of funding right now, Chairman of the Board Dr. Steve Davis said. That period should end Aug. 5, so be […]
presented by
A Path to Healing: Discovering Arizona’s PTSD Treatment Centers
Explore top PTSD treatment centers in Arizona, offering personalized care, holistic therapies and expert support to help individuals heal and reclaim their lives.
Stem cell company Athersys expects more R&D spending, potential partnerships in 2013
Cleveland-based Athersys (NYSE:ATHX) has a full plate as it continues to advance its “off the shelf” stem cell therapy, MultiStem, through clinical trials in several indications. That means shareholders can expect more R&D spending and potential new partnerships this year as the company continues developing MultiStem and its 5HT2C agonist program. Athersys CEO Gil Van […]
Texas biotech rounds up $2 million for platform to grow stem cells faster
A University of Texas spinoff company has pulled in $2 million to test a new technique for culturing non-embryonic stem cells. According to a regulatory filing, StemBioSys raised at least $2 million of a $3.5 million equity offering. A company representative was not available to elaborate, but CEO Dr. Steven Davis told the San Antonio […]
How one company is using Nobel Prize-winning stem cell research to develop better drugs
It’s easy to look at Nobel Prize winners and assume the greatness of their work. But it’s even more awe-inspiring to understand the research and see it in action. This year, the Nobel Prize in physiology or medicine was given to regenerative medicine researchers Sir. John B. Gurdon of the University of Cambridge and Shinya […]
Maker of stem cell modulators brings in $9.2 million for blood cancer trials
A California regenerative medicine firm raised $9.2 million and is planning new clinical trials for its stem cell modulator in patients with blood cancer. Read more.
Medical Megatrends Stem Cells — Part III
A cure for spinal cord injury? Diabetes? Macular degeneration? Hope or just hype? There are now some clinical trials using embryonic stem cells to treat serious diseases for which no other good therapy is currently available. But this is just the beginning of a major medical megatrend that will blossom forth in the coming years. […]